Menu
Fechar
HRS4R
Vull donar

ALBERT MIGUELA BENAVIDES

Neurodegeneració i Neuroinflamació
Firma
ALBERT MIGUELA-BENAVIDES
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1
Projectes
Publicacions

Projectes

Neurodegeneració i Neuroinflamació

PROCOGBIO Predicción de la progresión del deterioro cognitivo en la esclerosis múltiple combinando biomarcadores circulantes en sangre

Codi oficial: PI23/00517 Data inici: 01/01/2024 Data fi: 31/12/2026 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ, ANNA QUIROGA VARELA Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Woo MS, Brand J, Bal LC, Moritz M, Walkenhorst M, Vieira V, Ipenberg I, Rothammer N, Wang M, Dogan B, Loreth D, Mayer C, Nagel D, Wagner I, Pfeffer LK, Landgraf P, van Ham M, Mattern KM, Winschel I, Frantz N, Sonner JK, Grosshans HK, Miguela A, Bauer S, Meurs N, Müller A, Binkle-Ladisch L, Salinas G, Jänsch L, Dieterich DC, Riedner M, Krüger E, Heppner FL, Glatzel M, Puelles VG, Engler JB, Nyengaard JR, Misgeld T, Kerschensteiner M, Merkler D, Meyer-Schwesinger C, Friese MA

The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis.

CELL, 2025, 188 dx.doi.org/10.1016/j.cell.2025.05.029
Garcia-Sarreon, A, Quiroga-Varela, A, Gifreu, A, Lago, AB, Gutierrez, J, Gonzalez-Platas, M, Pons, JH, Benavides, AM, Coll-Martinez, C, Fulla, JG, Bravo, GA

Association of Human Leukocyte Antigens with Idiopathic Neuroimmunological Conditions

MULTIPLE SCLEROSIS JOURNAL, 2025, 31, 244-244
Alemany-Perna, B, Tamarit, J, Cabiscol, E, Delaspre, F, Miguela, A, Huertas-Pons, JM, Quiroga-Varela, A, Ruiz, MM, Dominguez, DL, Torrenta, L, Genis, D, Ros, J

Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients

MOVEMENT DISORDERS, 2024, 39, 1099-1108 dx.doi.org/10.1002/mds.29808
Tortosa-Carreres J, Cubas-Núñez L, Quiroga-Varela A, Castillo-Villalba J, Ramió-Torrenta L, Piqueras M, Gasqué-Rubio R, Quintanilla-Bordas C, Sanz MT, Lucas C, Huertas-Pons JM, Miguela A, Casanova B, Laiz-Marro B, Pérez-Miralles FC

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 88, 105734-105734 dx.doi.org/10.1016/j.msard.2024.105734
Bravo, GCA, Quiroga-Varela, A, Gifreu, A, Pons, JMH, Lago, AB, Benavides, AM, Ramió-Torrentà, L

Echopraxia, an underrecognized clinical sign in multiple sclerosis: a biological and neuroimaging framework

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 743-743
Bravo, GCA, Gifreu, A, Quiroga-Varela, A, Lago, AB, Pons, JMH, Benavides, AM, Torrenta, LRI

First case of rebound effect after Ozanimod discontinuation

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1081-1082
Pons, JMH, Coll-Martínez, C, Benavides, AM, Gifreu, A, Pont, JS, Bravo, GCA, Fulla, JG, Torrenta, LRI, Quiroga-Varela, A

Interleukin-8 plasma levels as a potential biomarker for predicting middle-term cognitive outcomes

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 976-977
Coll-Martínez, C, Pont, JS, Pons, JMH, Benavides, AM, Gifreu, A, Bravo, GCA, Quiroga-Varela, A, Ramió-Torrentà, L, Fulla, JG

Cognitive outcomes through MS disease course: 10-year follow-up

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 747-748
Coll-Martínez, C, Pons, JMH, Benavides, AM, Bravo, GCA, Gifreu, A, Pont, JS, Fulla, JG, Torrenta, LRI, Quiroga-Varela, A

Prognostic potential of plasma Interleukin-6 levels as biomarker for long-term cognitive performance

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 981-981
Benavides, AM, Pons, JMH, Coll-Martínez, C, Gifreu, A, Bravo, GCA, Torrenta, LRI, Quiroga-Varela, A

Circulating miR-197-3p and miR-1-3p in plasma as potential biomarkers of mitochondrial dysfunction in Primary Progressive Multiple Sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 589-590

Formulari de contacte

Coneix l’IDIBGI!

 menu